Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.
semaglutidetirzepatidesurvodutide
Diabetes, obesity & metabolismJan 2026
GLP-1 Research Tracker
Every clinical trial and published study on semaglutide, tirzepatide, and next-generation GLP-1 medications — curated with plain-language summaries.
234 studies tracked·6 compounds covered·Updated Jul 2026
Phase 1
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants.
orforglipron
Clinical pharmacology in drug developmentJan 2026
A Bibliometric Analysis Review of the Top 50 Most Cited Articles on Incretin-Based Therapy for Weight Reduction and Diabetes Management.
CureusJan 2026
Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss.
semaglutide
CureusJan 2026
The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case-control study.
semaglutideliraglutide
Therapeutic advances in musculoskeletal diseaseJan 2026
Post-sleeve gastrectomy weight loss: Role of botulinum toxin and semaglutide injections.
semaglutide
Endoscopy international openJan 2026
Real-world effectiveness, safety, and quality of life of biosynthetic semaglutide in Pakistani adults with type 2 diabetes mellitus: a study protocol.
semaglutide
Journal of pharmaceutical policy and practiceJan 2026
Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth.
tirzepatide
Frontiers in oncologyJan 2026
Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review.
semaglutidetirzepatideliraglutide
Frontiers in endocrinologyJan 2026
Guideline-Directed Medical Therapy for Diabetic Kidney Disease: Advances in Primary and Secondary Prevention.
CureusJan 2026
Pharmacotherapy for obesity management-Emphasizing the role of GLP-1 receptor agonist-based therapeutics.
Journal of clinical lipidologyJan 2026
Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction.
tirzepatide
International journal of heart failureJan 2026
Association Between Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Outcomes Based on Race and Sex Among Patients With and Without Diabetes Mellitus: A Meta-Analysis of Nine Randomized Controlled Trials.
Reviews in cardiovascular medicineJan 2026
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists.
Reviews in cardiovascular medicineJan 2026
Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Obesity: A Systematic Review and Meta-Analysis.
CureusJan 2026
Metabolic Inflammation as a Common Thread in Cardio-Endocrine Diseases: Toward a Unified Therapeutic Framework.
CureusJan 2026
The role of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in chronic obstructive pulmonary disease.
Expert review of clinical immunologyJan 2026
Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity - Campania Region.
tirzepatide
EXCLI journalJan 2026
The Metabolic Heart: Reframing Heart Failure With Preserved Ejection Fraction as a Systemic Cardio-Metabolic Syndrome.
CureusJan 2026
One small molecule for man, one giant leap for mankind with obesity.
orforglipron
Med (New York, N.Y.)Dec 2025
Get Weekly Research Updates
New clinical trials, study results, and plain-language summaries delivered to your inbox.
Free weekly newsletter · No spam, unsubscribe anytime